The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALKS | +13.5% | +95.85% | +14.39% | +481% |
| S&P | +15.06% | +95.03% | +14.29% | +1,665% |
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes reported strong earnings by exceeding both revenue and earnings expectations in its latest quarterly release.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $390.66M | -2.1% |
| Gross Profit | $339.70M | 1.0% |
| Gross Margin | 86.96% | 2.7% |
| Market Cap | $4.72B | 15.7% |
| Market Cap / Employee | $2.62M | 0.0% |
| Employees | 1.8K | -14.3% |
| Net Income | $87.10M | -8.0% |
| EBITDA | $100.80M | -13.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $521.20M | -2.6% |
| Accounts Receivable | $356.33M | -3.7% |
| Inventory | 191.9 | -1.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $66.22M | -81.6% |
| Short Term Debt | $6.46M | -28.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 15.61% | 0.0% |
| Return On Invested Capital | 8.85% | 7.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $137.19M | -1.2% |
| Operating Free Cash Flow | $150.20M | 2.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 14.26 | 13.19 | 15.72 | 13.73 | -3.81% |
| Price to Book | 3.50 | 3.60 | 3.66 | 3.12 | -3.98% |
| Price to Sales | 3.11 | 3.08 | 3.68 | 3.20 | 17.10% |
| Price to Tangible Book Value | 3.75 | 3.85 | 3.88 | 3.30 | -5.14% |
| Price to Free Cash Flow TTM | 14.83 | 11.81 | 11.57 | 10.04 | -20.30% |
| Enterprise Value to EBITDA | 36.98 | 24.27 | 224.47 | 38.43 | 23.98% |
| Free Cash Flow Yield | 6.7% | 8.5% | 8.6% | 10.0% | 25.48% |
| Return on Equity | 29.2% | 27.9% | 25.7% | 23.9% | -10.24% |
| Total Debt | $366.00M | $75.54M | $74.10M | $72.68M | -80.25% |
ALKS earnings call for the period ending June 30, 2022.
ALKS earnings call for the period ending March 31, 2022.
ALKS earnings call for the period ending December 31, 2021.
ALKS earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
